SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week

from BiotechTV - News · host BiotechTV

He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.

Episode metadata supplied by the publisher feed · Published Jan 15, 2026

Embed this episode

Attribution link and audio player

Ready to play

SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week

0:00 13:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 13 minutes long.

This episode was published on January 15, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!